ArticleCureus2026
Assessment of Perceived Knowledge and Beliefs Toward Cancer Immunotherapy Among Regional Healthcare Providers.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Cancer immunotherapy represents a rapidly advancing frontier in oncology. Its increasing integration with established treatment modalities underscores the necessity for healthcare providers (HCPs) to be well-informed. Awareness among HCPs is critical for effective multidisciplinary collaboration and optimal patient care. This study aimed to assess HCPs' awareness and perceptions of cancer immunotherapy. Methods A cross-sectional study was conducted using a self-administered questionnaire among HCPs in the Qassim region of Saudi Arabia between November 2022 and March 2023. The survey evaluated perceptions and self-reported knowledge regarding cancer immunotherapy and its associated side effects. Results Among 374 participants (mean age: 41 years; 62% male, 38% female), 35% had ≥10 years of professional experience. Overall knowledge was low, with 258 participants (69%) scoring poorly. A majority (201, 53.7%) considered chemotherapy the best treatment option, while 159 (42.5%) perceived immunotherapies as the most expensive modality. A significant knowledge gap was evident, with 269 HCPs (71.9%) reporting a lack of familiarity with immunotherapy and 163 (43.6%) expressing uncertainty about its effectiveness compared to other therapies. The need to address this knowledge deficit was affirmed by 304 respondents (81.3%). Conclusion This study reveals poor perceived knowledge of cancer immunotherapy among HCPs in the region, a prevalent preference for chemotherapy as the optimal treatment, and a common perception of immunotherapy as costly. To bridge this gap, we recommend promoting HCP engagement in specialized field workshops and updating educational curricula, as better knowledge will increase appropriate use and improve outcomes, which strengthens policy support and public trust.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.